Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR DIGIHALER versus ARMONAIR RESPICLICK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR DIGIHALER versus ARMONAIR RESPICLICK.
ARMONAIR DIGIHALER vs ARMONAIR RESPICLICK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARMONAIR DIGIHALER contains fluticasone furoate and umeclidinium, and vilanterol. Fluticasone furoate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, modulating gene expression to reduce inflammatory mediators. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine at M3 receptors, causing bronchodilation. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2 receptors, leading to smooth muscle relaxation and bronchodilation.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
2 inhalations (55 mcg each) orally twice daily for maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD).
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
None Documented
None Documented
Terminal elimination half-life of unchanged arformoterol is approximately 26 hours (range 21-30 hours). This supports twice-daily dosing with approximately 2 days to steady state.
Terminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30%
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid